Physician profile
David R Grech
NPI 1336128792
$4,088.45
in general payments reported to CMS, 2019-2025
32 companies · $659 in 2025
The $659 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $357 · 2021: $325 · 2022: $433 · 2023: $632 · 2024: $1,095 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $734.34 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $556.57 | 2021-2024 | Linq II, Onyx Frontier, Symplicity G3 |
| Janssen Pharmaceuticals, INC | $464.18 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $415.37 | 2021-2025 | Verquvo, Capvaxive |
| Sanofi-Aventis U.S. LLC | $325.75 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $220.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.70 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $149.27 | 2023-2025 | Nexletol |
| Abiomed | $139.67 | 2025 | |
| Amgen INC. | $121.45 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $115.01 | 2020 | |
| Alnylam Pharmaceuticals INC. | $66.57 | 2024-2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $62.02 | 2024 | Arcalyst |
| Abbott Laboratories | $51.37 | 2020-2023 | Gallant |
| Bayer Healthcare Pharmaceuticals INC. | $48.49 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $44.10 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $42.33 | 2022-2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.67 | 2020-2024 | Lifevest |
| Philips North America LLC | $33.61 | 2024 | (Ck7) Extended Holter |
| Cvrx, INC. | $33.28 | 2024-2025 | Barostim Neo System |
| Boston Scientific Corporation | $32.06 | 2025 | Watchman Flx |
| Inspire Medical Systems, INC. | $31.11 | 2024 | Inspire |
| Kestra Medical Technology Services, INC. | $28.72 | 2024 | Assure Wcd |
| Genzyme Corporation | $26.07 | 2022 | |
| Lundbeck LLC | $21.93 | 2019 | |
| Daiichi Sankyo INC. | $21.39 | 2024 | Injectafer |
| Edwards Lifesciences Corporation | $20.53 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $19.96 | 2025 | |
| Irhythm Technologies, INC. | $16.98 | 2021 | |
| Novo Nordisk INC | $15.10 | 2021 | |
| Gilead Sciences, INC. | $14.83 | 2019 | |
| Cmp Pharma, INC. | $11.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Grech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.